intrommune_icon_500x500.png
Intrommune Therapeutics Appoints Sergi Trilla, MD, MBA to its Scientific and Business Advisory Boards
28 juil. 2021 14h10 HE | Intrommune Therapeutics
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
intrommune_icon_500x500.png
Intrommune Therapeutics Names Chief Operating Officer
25 mars 2021 09h10 HE | Intrommune Therapeutics
NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other...
intrommune_icon_500x500.png
Research Presentations at the 2021 Annual AAAAI Meeting Highlight Limitations of Current Food Allergy Treatments and Further Validates Intrommune Therapeutics’ Approach
12 mars 2021 09h30 HE | Intrommune Therapeutics
NEW YORK, March 12, 2021 (GLOBE NEWSWIRE) -- The clinical and scientific team of Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing patient-friendly treatments...
intrommune_icon_500x500.png
Intrommune Therapeutics Publishes Peanut Allergy and Immunotherapy Report
23 févr. 2021 12h00 HE | Intrommune Therapeutics
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly immunotherapy platform for the treatment of...
intrommune_icon_500x500.png
Intrommune Receives IND Clearance From U.S. Food and Drug Administration for INT301
04 févr. 2021 09h13 HE | Intrommune Therapeutics
NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies,...
Intrommune Logo Only - 250k.jpg
Intrommune to Participate in BIO @ JPM During “J.P. Morgan Week 2021”
07 janv. 2021 17h35 HE | Intrommune Therapeutics
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, will...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Strikes Deal with Circuit Clinical®
20 oct. 2020 10h00 HE | Intrommune Therapeutics
NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Intrommune Therapeutics has announced an expanded partnership with Circuit Clinical, a leading Integrated Research Organization (IRO). Based on this deal,...
Intrommune Logo Only - 250k.jpg
Recent Peer-Reviewed Publication Supports Immunotherapy for the Treatment of Food Allergies
08 oct. 2020 09h50 HE | Intrommune Therapeutics
NEW YORK, Oct. 08, 2020 (GLOBE NEWSWIRE) -- A recent publication in the journal Immunotherapy reviews a variety of immunotherapy platforms for the treatment of food allergies. The article,...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Featured at Upcoming Investor Conferences
05 oct. 2020 14h55 HE | Intrommune Therapeutics
NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing patient-friendly food allergy therapies for peanut and other food allergies...
Intrommune Logo Only - 250k.jpg
Media Alert: Interest in Peanut Allergy Market Heats up in the Wake of Aimmune/Nestlé Deal
01 sept. 2020 15h55 HE | Intrommune Therapeutics
NEW YORK, Sept. 01, 2020 (GLOBE NEWSWIRE) -- The recent $2.6 billion acquisition of Aimmune by Nestlé Health Science has helped shed light on the global peanut allergy problem. In January 2020,...